Head-to-head · Cost-Efficiency Index
CoreAge Rx vs NexLife
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxNexLife
Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Visit NexLifeThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 63. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. NexLife still earns a C — Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | NexLife |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 63/100 |
| Semaglutide / mo | $99/mo | $165/mo (all doses, compounded) |
| Tirzepatide / mo | $149/mo | $215/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $1,188 | $1,980 |
| Tirzepatide / yr (modeled) | $1,788 | $2,580 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #185 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
NexLife
63/100Where the value is
- Flat pricing confirmed at every dose for both drugs — no per-mg escalation during titration, unlike most compounded competitors in this batch
- LegitScript certified with a named medical director (Adam Kennah, M.D.)
- States every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels
The tradeoffs
- The commonly advertised '$186/mo' tirzepatide headline requires a 12-month commitment; the true no-commitment month-to-month price is $215/mo — about 16% more
- No individual compounding pharmacy is named, only 'LegitScript-certified, NABP-accredited' pharmacies generically
Regulatory note: the FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. We still list and link to NexLife; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.